Biosplice Therapeutics announced on September 8, 2026, that the United Kingdom’s Medicines and Healthcare products Regulatory Agency had accepted its application for Lorecivivint™ as complete and valid.
Practice Changing OA Drug, in the Hands of UK Regulators
1 min read Premium comments

knee osteoarthritisintra-articular injectionLorecivivintdisease-modifying osteoarthritis drugMHRA marketing authorization
Author
React:
